Huprine Y - Tryptophan heterodimers with potential implication to Alzheimer's disease treatment.
Basic Information
ID: ALA4819137
Journal: Bioorg Med Chem Lett
Title: Huprine Y - Tryptophan heterodimers with potential implication to Alzheimer's disease treatment.
Authors: Mezeiova E, Hrabinova M, Hepnarova V, Jun D, Janockova J, Muckova L, Prchal L, Kristofikova Z, Kucera T, Gorecki L, Chalupova K, Kunes J, Hroudova J, Soukup O, Korabecny J.
Abstract: The search for novel and effective therapeutics for Alzheimer's disease (AD) is the main quest that remains to be resolved. The goal is to find a disease-modifying agent able to confront the multifactorial nature of the disease positively. Herewith, a family of huprineY-tryptophan heterodimers was prepared, resulting in inhibition of cholinesterase and neuronal nitric oxide synthase enzymes, with effect against amyloid-beta (Aβ) and potential ability to cross the blood-brain barrier. Their cholinesterase pattern of behavior was inspected using kinetic analysis in tandem with docking studies. These heterodimers exhibited a promising pharmacological profile with strong implication in AD.
CiteXplore: 33984470
DOI: 10.1016/j.bmcl.2021.128100
Patent ID: ┄